Thiery Berard-De Serres

Quebec, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

MBNL2 dysfunction in outer radial glial cells is associated with disrupted corticogenesis in congenital myotonic dystrophy.

MBNL2 dysfunction in outer radial glial cells is associated with disrupted corticogenesis in congenital myotonic dystrophy.

Journal: Neurobiology of disease

Published: November 05, 2025

MBNL2 dysfunction in outer radial glial cells is associated with disrupted corticogenesis in congenital myotonic dystrophy.

MBNL2 dysfunction in outer radial glial cells is associated with disrupted corticogenesis in congenital myotonic dystrophy.

Journal: Neurobiology of disease

Published: November 05, 2025

Generation of a control induced pluripotent stem cell line (CBRCULi014-A) derived from the lymphoblastoid cells of a pediatric individual.

Generation of a control induced pluripotent stem cell line (CBRCULi014-A) derived from the lymphoblastoid cells of a pediatric individual.

Journal: Stem cell research

Published: March 15, 2024

Generation of a lymphoblastoid-derived induced pluripotent stem cell line (CBRCULi015-A) from a patient with congenital myotonic dystrophy.

Generation of a lymphoblastoid-derived induced pluripotent stem cell line (CBRCULi015-A) from a patient with congenital myotonic dystrophy.

Journal: Stem cell research

Published: February 26, 2024

Generation of induced pluripotent stem cell lines from pediatric patients with congenital myotonic dystrophy (CBRCULi012-A and CBRCULi013-A) and age-matched controls (CBRCULi010-A and CBRCULi011-A)

Generation of induced pluripotent stem cell lines from pediatric patients with congenital myotonic dystrophy (CBRCULi012-A and CBRCULi013-A) and age-matched controls (CBRCULi010-A and CBRCULi011-A)

Journal: Stem cell research

Published: September 19, 2023

In vitro glycation of a tissue-engineered wound healing model to mimic diabetic ulcers.

In vitro glycation of a tissue-engineered wound healing model to mimic diabetic ulcers.

Journal: Biotechnology and bioengineering

Published: November 08, 2022

Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.

Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.

Journal: International journal of molecular sciences

Published: September 19, 2022

Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1.

Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1.

Journal: Human gene therapy

Published: July 07, 2022

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.

Journal: Gene therapy

Published: October 18, 2021

Deciphering the mechanisms underlying brain alterations and cognitive impairment in congenital myotonic dystrophy.

Deciphering the mechanisms underlying brain alterations and cognitive impairment in congenital myotonic dystrophy.

Journal: Neurobiology of disease

Published: August 12, 2021

Development of an innervated tissue-engineered skin with human sensory neurons and Schwann cells differentiated from iPS cells.

Development of an innervated tissue-engineered skin with human sensory neurons and Schwann cells differentiated from iPS cells.

Journal: Acta biomaterialia

Published: June 06, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026